Company: PCRX
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001628280-25-050176
Chunk: 123

Company: Pacira BioSciences, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 123
---
 of $2.2 million primarily related to third-party services and legal fees associated with the GQ Bio Acquisition.

During the nine months ended September 30, 2025, we recognized legal settlement costs of $7.0 million related to the settlement of the patent infringement suits against Fresenius Kabi USA, LLC, eVenus Pharmaceuticals Laboratories, Inc. and Jiangsu Hengrui Pharmaceuticals Co., Ltd.

During the three and nine months ended September 30, 2025, we recognized $23.1 million in other income upon receipt of a cash payment associated with the U.S. District Court for the District of Nevada issuing judgment declaring that RDF was 

Pacira BioSciences, Inc.  |  Q3 2025 Form 10-Q  |  50

required to repay us the royalties on EXPAREL sales that we previously paid under protest. In May and September 2025, RDF filed two notices of appeal which are pending.

During both the three and nine months ended September 30, 2025, we recorded a $25.9 million in-process research and development (IPR&D) impairment associated with our ZILRETTA shoulder asset due to revised completion timelines for clinical trials and commercial availability which directly impacted revenue forecasts, among other factors.

For more information on these events, see Note 3, GQ Bio Therapeutics Acquisition, Note 8, Goodwill and Intangible Assets, Note 10, Financial Instruments, Note 15, Contingent Consideration Charges (Gains), Acquisition-related Expenses, Restructuring and Other and Note 16, Commitments and Contingencies, to our condensed consolidated financial statements included herein. 

Other Income (Loss), Net

The following table provides information regarding other income, net during the periods indicated, including percent changes (dollar amounts in thousands):

Three Months EndedSeptember 30,% Increase / (Decrease)Nine Months EndedSeptember 30,% Increase / (Decrease)2025202420252024Interest income$8,534 $5,482 56%$20,437 $14,134 45%Interest expense(4,279)(4,689)(9)%(13,554)(11,889)14%(Loss) gain on early extinguishment of debt(983)— N/A(983)7,518 N/AOther, net(110)(122)(10)%(6,448)(320)100+%Total other income (loss), net